BIG
EBS icon

Brooklyn Investment Group’s Emergent Biosolutions EBS Stock Holding History

Brooklyn Investment Group’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-22,482
Closed -$275K – 1898
2025
Q4 		$275K Buy
+22,482
New +$241K 0.01% 1117
2025
Q2 		– Sell
-4,164
Closed -$20.2K – 3345
2025
Q1 		$20.2K Buy
4,164
+4,077
+4,686% +$33.7K ﹤0.01% 1163
2024
Q4 		$832 Buy
+87
New +$798 ﹤0.01% 1641

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Brooklyn Investment Group's EBS Position: Q1 2026 in Review

Brooklyn Investment Group sold out of Emergent Biosolutions (EBS) in Q1 2026, closing a stake of 22,482 shares — an estimated $275K sold.

Brooklyn Investment Group first reported a position in EBS in Q4 2024 and held it in 3 quarters. The position peaked at $275K in Q4 2025. 190 funds tracked by Wall St. Rank hold EBS as of Q1 2026.

  • Brooklyn Investment Group reported no remaining Emergent Biosolutions position as of Q1 2026 after selling out during the quarter.
  • Brooklyn Investment Group sold 22,482 Emergent Biosolutions shares in Q1 2026, an estimated $275K.
  • Brooklyn Investment Group first reported a position in Emergent Biosolutions in Q4 2024 and held it in 3 quarters.
  • Brooklyn Investment Group's Emergent Biosolutions position peaked at $275K in Q4 2025.
  • 190 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2026.

Based on Brooklyn Investment Group's 13F filing for Q1 2026, filed 29 Apr 2026.